NEW YORK (GenomeWeb News) – Signal Genetics plans to offer 2,272,000 shares of common stock at $10 to $12 per share through its initial public offering, the cancer molecular diagnostics company said in a prospectus filing with the US Securities and Exchange Commission.

Assuming an average price of $11 per share, the company expects to raise about $25 million through the offering, if the underwrites exercise their full over-allotment option for an additional 340,800 shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.